Imaging and drug delivery using theranostic nanoparticles

By S. M. Janib, Ara S. Moses, J. Andrew MacKay. Advanced Drug Delivery Reviews, 2010

1,134 citations recorded by the source corpus.

Nanoparticle technologies are significantly impacting the development of both therapeutic and diagnostic agents. At the intersection between treatment and diagnosis, interest has grown in combining both paradigms into clinically effective formulations. This concept, recently coined as theranostics, is highly relevant to agents that target molecular biomarkers of disease and is expected to contribute to personalized medicine. Here we review state-of-the-art nanoparticles from a therapeutic and a diagnostic perspective and discuss challenges in bringing these fields together. Major classes of nanoparticles include, drug conjugates and complexes, dendrimers, vesicles, micelles, core–shell particles, microbubbles, and carbon nanotubes. Most of these formulations have been described as carriers of either drugs or contrast agents. To observe these formulations and their interactions with disease, a variety of contrast agents have been used, including optically active small molecules, metals and metal oxides, ultrasonic contrast agents, and radionuclides. The opportunity to rapidly assess and adjust treatment to the needs of the individual offers potential advantages that will spur the development of theranostic agents.

Subfields: Biomaterials, Biomedical Engineering, Polymers and Plastics

View Paper: https://www.semanticscholar.org/paper/71bb13f36da4cf95e72229c342cf12daa2a0deb6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. F. Danhier
2. V. Préat
3. Jun Wu

In Biomedical Engineering

1. Hak Soo Choi
2. Moungi G. Bawendi
3. F. Danhier
4. John V. Frangioni
5. V. Préat
6. Jun Wu

Citations in the corpus

• Mesoporous silica nanoparticles in target drug delivery system: A review (2015, neutral): “[64,65] Ideally, these nanomaterials will be suitable for long-term quantitative imaging at low doses and safely cleared from the body after imaging is complete.”
• Rapid Translocation of Nanoparticles from the Lung Airspaces to the Body (2010, background): “Nanoparticles have been proposed as diagnostic, therapeutic and theranostic agents for a wide variety of human disease”
• PLGA-based nanoparticles: an overview of biomedical applications. (2012, background): “Theragnostics may combine passive and active targeting, environmentally responsive drug release, molecular imaging and other therapeutic functions into a single platform [120].”